NCT06052930 is a NA clinical trial of HTC Vive™ Pro in Parkinson Disease, sponsored by Campus Neurológico Sénior.

Who is sponsoring NCT06052930?

NCT06052930 is sponsored by Campus Neurológico Sénior.

What drugs are being tested in NCT06052930?

Interventions in NCT06052930: HTC Vive™ Pro.

What condition does NCT06052930 study?

NCT06052930 studies Parkinson Disease.

Is NCT06052930 still recruiting?

NCT06052930 is currently completed. Last updated 25 September 2023.

Last reviewed 2023-09-25 · How we verify

NCT06052930

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immersive Virtual Reality for the Non-pharmacological Management of Parkinson's Disease

Completed NA Last updated 25 September 2023

What this trial tests

NA trial testing HTC Vive™ Pro in Parkinson Disease in 30 participants. Completed in 12 August 2023.

Timeline

19 January 2023

Primary endpoint
12 August 2023

12 August 2023

Quick facts

Lead sponsor	Campus Neurológico Sénior
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	30
Start date	19 January 2023
Primary completion	12 August 2023
Estimated completion	12 August 2023
Sites	1 location across Portugal

Drugs / interventions tested

HTC Vive™ Pro

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

Campus Neurológico Sénior

Who can join

18 and older, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to evaluate the feasibility, safety and efficacy of an immersive virtual reality (IVR) exergaming using a head-mounted display in Parkinson's disease symptomatic control. This is a parallel-group, single-blinded, randomized controlled trial. The intervention group perform 12 weeks of physiotherapy and IVR, whereas the control group have 6 weeks of physiotherapy only, followed by 6 weeks of physiotherapy and IVR. The primary outcome is the symptomatic effect of the intervention as measured by the change from baseline in Time Up and Go (TUG) test with cognitive dual-task (TUG cognitive).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Safety of Immersive Virtual Reality for the Management of Parkinson's Disease.
Pimenta Silva D, Pona-Ferreira F, Santos B, Campo-Prieto P, et al · · 2024 · cited 6× · PMID 39771922 · DOI 10.3390/s24248188

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other Campus Neurológico Sénior trials

Trials by the same sponsor.

NCT04699617 — The Feasibility and Efficacy of an Immersive Virtual Reality Software in Parkinson's Disease Patients · NA · completed
NCT03891069 — Feasibility of the AHA Exergame System in Parkinson's Disease Patients · NA · completed
NCT03123601 — Feasibility of Risk Sign Displays to Prevent Falls, Dehydration and Pulmonary Aspiration in Nursing Homes · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06052930 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Campus Neurológico Sénior
Last refreshed: 25 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06052930.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing